Zacks: Evotec AG (EVTCY) Given Consensus Rating of “” by Analysts
Shares of Evotec AG (NASDAQ:EVTCY) have been given a consensus broker rating score of 3.00 (Hold) from the one analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.
Zacks has also given Evotec AG an industry rank of 167 out of 265 based on the ratings given to its competitors.
EVTCY has been the topic of several recent research reports. Berenberg Bank restated a “buy” rating on shares of Evotec AG in a research report on Wednesday, May 10th. Deutsche Bank AG restated a “neutral” rating on shares of Evotec AG in a research report on Friday, March 31st. Finally, DZ Bank AG reiterated a “sell” rating on shares of Evotec AG in a research report on Wednesday, July 12th.
COPYRIGHT VIOLATION NOTICE: “Zacks: Evotec AG (EVTCY) Given Consensus Rating of “” by Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/17/zacks-evotec-ag-evtcy-given-consensus-rating-of-by-analysts.html.
Shares of Evotec AG (NASDAQ:EVTCY) traded up 0.09% during trading on Monday, reaching $32.45. The company’s stock had a trading volume of 1,477 shares. Evotec AG has a 1-year low of $8.54 and a 1-year high of $33.13. The stock has a 50 day moving average of $29.34 and a 200-day moving average of $20.68. The company has a market capitalization of $2.27 billion and a PE ratio of 55.95.
Evotec AG Company Profile
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.